Clinical Trials

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

Do you have high blood pressure, high A1C levels, or have overweight or obesity? Researchers are testing if a program helps increase physical activity for people at risk of cardiovascular disease. Participants will receive remote coaching and wear a physical activity tracker. To join, you must be 40 to 70 years old and can access the internet. The study is taking place in Pittsburgh, Pennsylvania.

Are you at least 18 years old and have heart failure? Researchers in this clinical trial are testing whether a new type of hormone therapy may help with symptoms and quality of life for people who have heart failure. Participants will take medication by mouth daily. The study is taking place in Philadelphia, Pennsylvania.

Does your child have Down Syndrome? Did they have a complete atrioventricular septal defect (CAVSD) repair within the first year of their life? Researchers in this study are investigating how the
brain develops in children with Down Syndrome who have congenital heart disease. To participate, your child must be between 5 and 12 years old and have Down Syndrome. The study will enroll children who have congenital heart disease as well as children who do not have congenital heart disease. The study is taking place in locations in Delaware, Georgia, Indiana, Massachusetts, Michigan, Missouri, New York, Ohio, Pennsylvania, South Carolina, Texas, Utah, Washington, D.C., and Toronto, Canada

Do you or one of your children have a congenital heart defect? This study will find both common genetic causes of congenital heart disease and ways that genes influence results of medical treatment. To participate in this study, you or your child must have congenital heart disease. This study is located in Los Angeles, Palo Alto, and San Francisco, California; New Haven, Connecticut; Boston, Massachusetts; New York and Rochester, New York; Philadelphia, Pennsylvania; and Salt Lake City, Utah.

Is your child black and 8 to 11 years old? This study is testing a way of enhancing sleep in children with the goal of preventing obesity. To participate in this study, your child must be 8 to 11 years old and must be black or African American. This study is located in Philadelphia, Pennsylvania.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Do you have heart failure with reduced ejection fraction and thyroid problems? This study will test whether hormone therapy with liothyronine is safe and effective for treating people who have heart failure with reduced ejection fraction and low triiothyronine (T3) syndrome. Low T3 syndrome is a type of thyroid hormone that helps control many functions of your body. To participate in this study, you must be at least 18 years old and diagnosed with heart failure with reduced ejection fraction. This study is located in Philadelphia, Pennsylvania.

Does your child have overweight or obesity? This study is exploring the link between obesity and sleep deprivation in children. Researchers will test whether participants who do not get enough good quality sleep have trouble making healthy food choices. Participants in this study must be 8 to 12 years old and have overweight or obesity. This study takes place in Pittsburgh, Pennsylvania; and Providence, Rhode Island.

Do you have heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD)? This study is testing the effectiveness of thyroid hormone therapy with a medicine called liothyronine (LT3) in individuals HFrEF. To participate in this study, you must be at least 18 years old and have Class I, II, or III heart failure. This study takes place in Philadelphia, Pennsylvania.